



Christopher M. Parker

he/him/his
Associate

Chicago
+1 312-558-8085

Chris concentrates his practice in navigating the complexities of internal and government investigations, regulatory challenges, banking litigation, and complex commercial litigation for clients in the financial services and health care industries.

Chris is a litigation associate who maintains a focus on the Health Care and Life Sciences sector. He regularly advises health care clients on regulatory matters, including those involving federal controlled substance regulations and risk management. Chris is highly experienced in navigating the intricate complexities of compliance with the Controlled Substances Act, particularly during investigations initiated by the Drug Enforcement Administration.

In addition to advising clients on regulatory matters, Chris has substantial experience defending clients in connection with a wide range of issues arising under both criminal and civil statutes. These include the False Claims Act (FCA) and related *qui tam*/whistleblower litigation, government program fraud, the Anti-Kickback Statute, health care fraud, and government contracting fraud.

Chris also counsels clients on the development and enhancement of compliance programs, providing strategic guidance for achieving compliance objectives and minimizing the risk of government investigations. He has

successfully defended financial services institutions in complex commercial litigation and government investigations, including class actions, mass tort, and contractual disputes. Chris is experienced in all phases of litigation, including case assessment and strategy development, briefing and arguing motions, and managing all aspects of discovery in complex litigation. He is skilled in defending and taking depositions, as well as preparing cases and witnesses for trial.

Key Matters

ANTITRUST

- Represents clients seeking antitrust approval before the FTC and state attorneys general
- Represented a client in obtaining antitrust clearance for a transaction before the DOJ

CLASS ACTIONS

- Defending a global financial institution against several high-profile class actions and single-plaintiff actions
- Defended a higher education institution against a COVID-19 class action, resulting in dismissal at the motion to dismiss stage

COMPLEX COMMERCIAL LITIGATION

- Represented a large insurance company in litigation over alleged non-payment of insurance commissions, resulting in dismissal at the motion to dismiss stage

GOVERNMENT AND INTERNAL INVESTIGATIONS

- Representing financial institution in investigation by Illinois Attorney General
- Representing financial institutions before the Consumer Financial Protection Bureau
- Representing individuals in criminal and civil DOJ, SEC, and OAG investigations
- Representing medical device manufacturer in DOJ investigation
- Representing pharmaceutical companies in DEA investigations
- Representing individuals and companies against False Claims Act allegations
- Representing individuals in high-profile higher education internal investigations

PRO BONO

- Represented a client in a state criminal matter that resulted in all felony charges being dropped and expunged from the client's record
- Successfully represented a client in divorce proceedings
- Representing a client seeking relief related to delay of medical treatment claims under 42 U.S.C. 1983

Recent Experience

Allscripts' Sale of EPSi to Strata Decision Technology

Recognitions

- Recognized by *Best Lawyers: Ones to Watch® in America* – Criminal Defense: White-Collar, 2024–2025
 - The National Black Lawyers' (NBL) "Top 40 Under 40"
 - CALI Award – Legal Writing
-

Activities

Chris actively participates in the firm's *pro bono* program, where he has represented defendants in criminal matters in Illinois state court and clients in the Northern District of Illinois. Chris is a member of the firm's Health Care and Life Science Group, where he leads associate engagement related to health care fraud and abuse issues and regularly publishes articles on the firm's [Government Program Fraud, False Claims Act & Qui Tam Litigation Playbook](#). Chris is an associate advisor to the firm's Black Lawyers Network. He is also Vice President of the Chicago chapter alumni board for The University of Maryland and an active member of the Chicago Bar Association.

Credentials

EDUCATION

Chris received his J.D. from The University of Chicago in 2018. He received his B.S., in psychology and neuroscience from The University of Maryland, College Park in 2012.

ADMISSIONS

- Illinois

Related Insights & News

- "[2023 DOJ FCA Enforcement: Expectations for Future](#)," Bloomberg Law, Co-author, April 5, 2024
- "[DOJ Further Pursues False Claims Act Violations Related to Fraudulent Paycheck Protection Program Loans](#)," Co-author, Aug. 15, 2023
- "[DOJ Continues to Crack Down on Health Care Fraud Violations, Announcing Convictions and Enforcement Activity](#)," Co-author, Aug. 14, 2023
- "[June 2023 FCA Settlement Wrap-Up: DOJ Continues to Crack Down on Health Care Fraud](#)," Co-author, Aug. 14, 2023
- "[DOJ's 2022 FCA Recoveries Announcement Reveals One of the Smallest Hauls in Recent Years, But Indicates a Different 2023 Outlook](#)," Co-author, March 28, 2023
- "[DOJ Continues Pursuit of False Claims Act Violations Related to Fraudulent Paycheck Protection Program Loans](#)," Co-author, Feb. 28, 2023
- "[NortonLifeLock Found Liable After FCA Trial, But Government Leaves Damages Money On The Table](#)," Co-author, Feb. 27, 2023
- "[DOJ Scrutiny of EHR Vendors Continues with \\$45 Million Settlement For Alleged Kickbacks and False Claims](#)," Co-author, Nov. 14, 2022

- “8th Circ. Ruling Raises Bar for Anti-Kickback FCA Claims,” Law360, Co-author, Aug. 10, 2022
 - “[DOJ Reaches \\$20 Million Agreement with BayCare Health Systems to Settle Claims of Allegedly Improper Donations to Increase Medicaid Funding](#),” Co-author, May 9, 2022
 - “[DOJ Continues to Use the False Claims Act to Protect PPP Funds](#),” Co-author, Sept. 7, 2021
 - “[DOJ Announces \\$22 Million False Claims Act Settlement with the University of Miami for Provider-Based Rule Violations Involving Laboratory Tests](#),” Co-author, June 17, 2021
 - “[FDA Publishes Guidance on Remote Interactive Evaluations for Oversight of Drug Manufacturing and Bioresearch Monitoring Facilities During the COVID-19 Public Health Emergency](#),” Co-author, May 26, 2021
 - “[FDA Enforcement Action Against Manufacturers for REMS Non-Compliance Reflects Agency Priorities During the Pandemic](#),” Co-author, April 16, 2021
 - “[Eli Lilly Prevails in Blocking Immediate Implementation of HHS’s 340B Drug Discount Rule Involving Dispute Resolution Between Manufacturers and Covered Entities](#),” Co-author, March 22, 2021
-

BLOG

Future FCA Enforcement Expectations in Light of New Administration Priorities and 2024 Recoveries
MAY 1, 2025

BLOG

Federal Jury Finds No Liability for SuperValu in FCA Case Remanded for Trial by SCOTUS
APRIL 2, 2025

BLOG

First Circuit Joins Circuit Split in Favor of “But For” Causation Required To Show Falsity in AKS-Based False Claims Act Cases
MARCH 13, 2025

BLOG

Winston Kicks Off Sixth Cohort of D&I Associate Sponsorship Program and Graduates the Class of 2023-2024
NOVEMBER 25, 2024

RECOGNITIONS

Winston Attorneys Recognized in *Best Lawyers: Ones to Watch® in America* 2025
AUGUST 15, 2024

BLOG

Winston Hosts Annual 1L LCLD Scholars Roundtable
JUNE 17, 2024

BLOG

2023 DOJ FCA Enforcement: Expectations for Future

BLOG

Winston & Strawn Launches Fifth Cohort of D&I Associate Sponsorship Program
OCTOBER 19, 2023

RECOGNITIONS

Winston Attorneys Recognized in *Best Lawyers: Ones to Watch® in America* 2024
AUGUST 17, 2023

BLOG

DOJ Further Pursues False Claims Act Violations Related to Fraudulent Paycheck Protection Program Loans
AUGUST 15, 2023

BLOG

DOJ Continues to Crack Down on Health Care Fraud Violations, Announcing Convictions and Enforcement Activity
AUGUST 14, 2023

BLOG

June 2023 FCA Settlement Wrap-Up: DOJ Continues to Crack Down on Health Care Fraud
AUGUST 14, 2023

Capabilities

Antitrust/Competition

Commercial Litigation & Disputes

Financial Services Litigation

Government Investigations, Enforcement & Compliance

Government Program Fraud, False Claims Act & Qui Tam Litigation

Litigation/Trials

Mergers & Acquisitions

Public Companies

Private Equity

Private Investment Funds

Health Care

Life Sciences

Medical Devices